Therefore, inhibition of FcRn is an attractive novel therapeutic concept for IgG-mediated autoimmune diseases like Graves’ hyperthyroidism, where acclerated antibody catabolism and the associated reduction in the levels of circulating pathogenic TRAb would be benefical. This evidence concerns the gene FCGRT and Graves disease.